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doi:10.1016/j.ejvs.2010.10.004Abstract Objective: To investigate the in vitro effects of detergent sclerosants sodium tet-
radecyl sulphate (STS) and polidocanol (POL) on clot formation and lysis.
Materials and methods: clot kinetics were assessed in whole blood by thromboelastography
(TEG) and rotational thromboelastometry (ROTEM). Fibrinogen was measured by the Clauss
method in plasma and factor XIII (FXIII) by enzyme-linked immunosorbent assay (ELISA).
Turbidity measurements were used to assess clot lysis in plasma, and fibrinolysis in non-
cross-linked and cross-linked fibrin. D-dimer was measured by VIDAS, STALiatest and
AxSYM assays.
Results: Strong clots were formed at low sclerosant concentrations (0.075e0.1%). At midrange
concentrations (0.15% STS, 0.15e0.3% POL), both agents inhibited the contribution of platelets
to clot firmness and formed weak clots prone to lysis. At higher concentrations (STS 0.3% and
POL 0.6%), clot formation was inhibited. STS destroyed FXIII at 0.15% and fibrinogen at
0.6%. Neither sclerosant had a significant effect on cross-linked fibrin, but STS had a lytic
effect on non-cross-linked fibrin. STS caused an artefactual elevation of D-dimer in the VIDAS
assay when fibrinogen was present.
Conclusion: Detergent sclerosants demonstrated a trimodal effect on clot formation, initiating
strong clots at low concentrations, weak clots at midrange concentrations and preventing clot
formation at higher concentrations. Neither agent had fibrinolytic activity.
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Detergent sclerosants, sodium tetradecyl sulphate (STS) and
polidocanol (POL), function by lysing the intimal lining of
blood vessels, exposing the underlying collagen with the
ultimate aim of inducing endovascular fibrosis. These agents
were historically assumed to achieve this by forming a clot
within the target vessel, the organisation ofwhich could lead
to vessel fibrosis and the lysis of which would lead to vessel
recanalisation and treatment failure.1 Our group has previ-
ously shown that these detergents are biologically active and
interfere with the coagulation, anti-thrombotic and fibrino-
lytic mechanisms.2e4 We have also shown that these agents
have a concentration-dependent effect on the coagulation
system in vitro with STS exhibiting anticoagulant activity at
>0.3%, while both agents demonstrate procoagulant activity
at lower concentrations.2e4 Nonetheless, the direct effect of
sclerosants on clot formation and lysis was not previously
investigated and was the subject of the present study.
The ultimate step in the formation of a fibrin clot is the
conversion of soluble fibrinogen to insoluble fibrin. This
process is mediated by thrombin, which also activates
Factor XIII (FXIII). Fibrin monomers are first assembled in
a non-covalent fashion and then covalently cross-linked
by activated FXIII (FXIIIa). Cross-linking enhances the
mechanical strength of the fibrin polymer, and leads to
increased clot stability, stiffness and resistance to fibrino-
lysis and deformation.5
Fibrin is degraded by plasmin generated from plasmin-
ogen by the action of tissue plasminogen activator (t-PA) in
blood and urokinase in tissues. The enzymatic degradation of
fibrin leads to the formation of fibrin degradation products
and, in particular, D-dimer. As shown by the authors, both
sclerosants interferewith fibrinolytic enzymes and inhibitors
and demonstrate antifibrinolytic activity.4 Here, we studied
the direct lytic effects of sclerosants on FXIII, fibrinogen
and fibrin and their potential for generation of D-dimer.
Materials and Methods
Materials
The following were used in this study: STS (FIBRO-VEIN 3%;
Australian Medical and Scientific, NSW, Australia); POL
(AETHOXYSKLEROL 3%; Chemische Fabrik Kreussler, Wies-
baden, Germany); TEG reagents (Haemoscope, IL, USA);
ROTEM reagents (Pentapharm, Munich, Germany); Echis
carinatus venom (ECV; RUDINtest, Haematex Research,
NSW); urea, low-melting-point agarose (type VII), Agkis-
trodon rhodostoma venom (ARV) and hydrolysed gelatin
(Sigma Chemical, MO, USA); human thrombin (Enzyme
Research Laboratories, IN, USA); recombinant human t-PA
(Haematologic Technologies, Vermont, USA) and bovine
serum albumin (BSA; Bovogen, Victoria, Australia).
Sample collection for fresh-frozen plasma (FFP)
Normal plasma (NP) was collected as FFP derived from
donor blood unsuitable for clinical indications and obtained
from the Australian Red Cross Blood Transfusion Service,Sydney. Samples were collected in acid citrate dextrose
(ACD) venous blood vacuum collection tubes.
Preparation of platelet-rich (PRP) and platelet-poor
plasma (PPP)
Centrifugation of whole blood (WB) for 10 min at 150 g
was performed to generate platelet-rich plasma (PRP) and
for 30 min at 1700 g to generate platelet-poor plasma
(PPP).
Preparation of freeze-dried plasma
Freeze-dried samples were prepared using NP (2.0 ml, 0.5%
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES)) dispensed into siliconised vials spiked with scle-
rosants to a final stated concentration (0%, 0.075%, 0.1%,
0.3%, 0.6% and 1%). The vials were frozen at 50 C and
vacuum dried for 2 days. Prior to testing, each vial was
reconstituted with 2 ml of water.
Preparation of fibrin agarose gel
Fibrinogen was isolated from NP by precipitation with
20% ammonium sulphate. Fibrinogen solution and low-
melting point agarose (2%w/v in 0.1 M sodium chloride
(NaCl), 0.02 M HEPES pH 7.0, 37 C) were mixed, 0.1 U ml1
thrombin and 0.01 M calcium chloride (CaCl2) were added,
and 0.1-ml volumes were dispensed into pre-warmed
microwells. For non-cross-linked fibrin, thrombin was
replaced with 0.0001% ARV (containing the thrombin-like
enzyme Ancrod) without CaCl2. The agarose set on cooling
and the fibrinogen within each well was slowly converted
with time to non-cross-linked fibrin (with ARV) and to cross-
linked fibrin (with thrombin that activates FXIII). Urea (6M),
known to dissolve non-cross-linked fibrin but not cross-
linked fibrin, was used as a control to confirm the cross-
linking status of the two types of fibrin agarose gels.6
Clot kinetics
Clot viscoelastic properties were assessed by thromboe-
lastography (TEG, Haemoscope) and rotational throm-
boelastometry (ROTEM, Pentapharm).7 Both systems use
a vertical pin within a cup that contains the WB sample. In
TEG, the cup oscillates and the pin is stationary whereas
in ROTEM, the cup is stationary while the pin oscillates.
As a clot forms between the cup and the pin, the reduction
in transmitted rotation from the cup to the pin (TEG)
or impedance to the oscillatory movement of the pin
(ROTEM) is detected and a trace is generated (Fig. 1(a)).
WB was collected from consenting healthy volunteers
on no medications or supplements into vacutainer tubes
containing 0.105 M buffered sodium citrate (BD Diagnostics,
Basel, Switzerland) and spiked with increasing concentra-
tions of sclerosants. Parameters measured are detailed in
Table 1 and assays performed are summarised in Table 2.
For TEG, 1 ml volumes of WB-spiked samples were
pipetted into Kaolin vials. A total of 20 ml of 0.2 M CaCI2
was placed in each cup followed by 300 ml of the Kaolin-
spiked samples.
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Figure 1 (a) Diagrammatic representation of a typical TEG/ROTEM trace indicating the commonly reported variables. r,
reaction time; CT, clotting time; k, coagulation time; CFT, clot formation time; MA, maximum amplitude; MCF, maximum clot
formation. (b) Representative sclerosant clot kinetics as analysed by ROTEM. Clot firmness <20 mm is marked with pink, and
20 mm with blue. Green line indicates no clot formation. Cn, concentration; Mid., midrange. (c) TEG/ROTEM parameters
measured in various assays. In FIBTEM, CFT is indefinitely prolonged as by definition, no strong clots with amplitudes >20 mm
(which requires a contribution from platelets) can be achieved. This is a normal finding for FIBTEM (NATEM, n Z 5; other assays,
n Z 2; STS and POL).
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Table 1 TEG and ROTEM parameters measured in this study.
TEG ROTEM Description
Reaction time (r) Clotting Time (CT) The time from beginning of measurement until clot formation
at 2 mm amplitude. This value represents the initiation of clotting
and formation of fibrin.
Coagulation
time (k)
Clot Formation Time (CFT) The time from initial clot formation at 2 mm until a firm clot of 20 mm
amplitude is formed. It represents fibrin polymerization and
cross-linking.
e Clot Formation Rate (CFR) The rate of clot formation based on a, the angle between the
baseline and a tangent to the curve running through the 2 mm
amplitude.
Maximum
Amplitude (MA)
Maximum Clot Firmness (MCF) Maximum amplitude of the trace representing maximum clot firmness.
It represents the increasing stabilisation of the clot by the
polymerised fibrin, platelets and FXIII.
Coagulation
Index (CI)
e This value is derived from r, k, a and MA and functions as an overall
assessment of coagulation, with values less than 3.0 signifying a
hypocoagulable state and values over þ3.0 indicating
hypercoagulability.28
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STARTEM reagent (0.2 M CaCl2 in HEPES pH 7.4 buffer) was
placed in each cup followed by 20 ml of the relevant reagent
per assay (EXTEM, INTEM, APTEM or FIBTEM) or 20 ml of
RUDINtest (ECATEM) or no other reagent (NATEM). A total
of 300 ml volumes of WB-spiked samples were then added.
All TEG and ROTEM assays were performed at 37 C
and run for 30 min except NATEM, which was run for 60 min
due to the prolonged initial clotting time.
Clot lysis time (CLT)
NP (FFP, 1 ml) was briefly mixed with small volumes of t-PA
stock solution to a final concentration of 25 ng l1.Table 2 TEG and ROTEM assays used in this study and reage
Assays Reagent Interpretation
TEG Calcium Chloride (CaCl2)
þ Kaolin
Thromboelastography
of sclerosants in the a
NATEM ‘STARTEM’ (CaCl2) Non-activated (NA) Th
towards any kind of c
provides a general ove
INTEM CaCl2 þ Ellagic acid
þ Phospholipids
Intrinsic pathway TEM
of the contact system
intrinsic pathway.
EXTEM CaCl2 þ Tissue factor (TF) Extrinsic pathway TEM
but consistent activat
ECATEM Echis Carinatus
Venom (ECV)
Ecarin TEM, ECATEM,
thrombin. ECATEM eva
the conversion of prot
fibrin from fibrinogen.
other plasma clotting
APTEM CaCl2 þ TF þ Aprotinin Aprotinin TEM, APTEM
reagent together with
compared with EXTEM
and the abnormal EXT
FIBTEM CaCl2 þ TF þ Cytochalasin D Fibrinogen TEM, FIBTE
cytoskeletal re-organi
contribution of clottin
is compared with EXT
The FIBTEM maximum
than the EXTEM (50e7Volumes (0.1 ml) were distributed into microwells and
mixed with increasing concentrations of sclerosants.
Volumes (0.1 ml) of thrombin (2U ml1) were then added
and the mixtures containing approximately 50% diluted
NP were allowed to clot. Turbidities were determined
periodically at 414 nm.
Interaction with exogenous t-PA
A total of 1.0 mg l1 of t-PA in 0.2% hydrolysed gelatine
(protein-poor) and 8.0 mg l1 in NP (protein rich) was pre-
incubated briefly with serial dilutions of sclerosants in
NaCl pH 7.0 buffer. 0.02 ml volumes were applied to fibrinnts used in each assay.
(TEG) was used to assess the global effects
ssay, the clotting cascade was activated with kaolin.
romboelastometry (TEM), NATEM, is sensitive
oagulation activation or inhibition in the sample and
rview of the haemostatic process.
, INTEM, is an assay that initiates a controlled activation
using ellagic acid and phospholipids to evaluate the
, EXTEM, uses a stabilised preparation of TF for a mild
ion of coagulation to examine the extrinsic pathway.
uses ECV to mediate the conversion of prothrombin to
luates the final two steps of the coagulation cascade i.e.
hrombin to thrombin and the subsequent generation of
The trace generated is independent of phospholipids and
factors.
, incorporates a plasmin inhibitor (aprotinin) in the ap-TEM
ex-TEM activation. The trace generated by this assay is
. In presence of fibrinolysis, aprotinin will inhibit fibrinolysis
EM trace will be corrected to a normal trace in APTEM.
M, incorporates Cytochalasin D, an inhibitor of platelet
sation. The trace generated would represent the
g factors and in particular fibrinogen to clot strength and
EM to assess the contribution of platelets to clot formation.
clot firmness (MCF) normal range is much lower (9e25 mm)
2 mm).
Figure 2 Clot lysis times with increasing concentrations of
STS (2a) and POL (2b) (n Z 2, 0%, , 0.05%, : 0.1%,
D 0.15%).
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were determined periodically at 414 nm.
Fibrinogen
Fibrinogen levels were measured in freeze-dried plasma
samples by the Clauss method,8 using a Thrombin reagent
(Dade Behring, Marburg, Germany) on an STA-R analyzer
(Diagnostica Stago, Asniere, France).
FXIII
Fresh donor WB, PRP and PPP samples containing serial
dilutions of sclerosants were prepared on non-coated plates
and tested following the standardprocedure in theFXIII ELISA
kit (EF 1013-1, Assaypro, MI, USA). In control experiments,
serial dilutions of sclerosants in 5%BSAwere spikedwith 12 ng
of FXIII and tested in the assay system (inter-assay coefficient
of variation: 6.8%). All assays were done in duplicate.
Fibrinolytic activity
Serial dilutions of sclerosants and t-PA (0.02 ml, 25 ng ml1)
in 0.1% BSA or hydrolysed gelatin buffer were applied to
cross-linked and non-cross-linked fibrin agarose gels
(0.1 ml) and incubated overnight at 37 C.
0.1 ml volumes of 2% cross-linked fibrin powder9 sus-
pended in HEPES-buffered saline were dispensed into
microwells, mixed with 0.1 ml of sclerosant dilutions and
incubated for 4 h at 37 C.
For both methods, turbidities were measured periodi-
cally at 414 nm following the incubation.
D-dimer
D-dimer was measured in freeze-dried samples by the
VIDAS D-dimer Exclusion assay (bioMe´rieuxsa, Marcy-
l’E´toile, France) on the Mini-VIDAS instrument (bioMe´rieux
Vitek, MI, USA), AxSYM D-dimer (Abbott Laboratories, IL,
USA) and STALiatest D-dimer (Diagnostica Stago).
To investigate the observed elevation of D-dimer by STS
(see Results 7), the D-dimer levels were re-measured in the
following samples using the VIDAS assay:
1 Original plasma samples following removal of a previ-
ously reported STS-induced precipitate2;
2 Serial dilutions of STS in saline or in VIDAS kit diluent;
3 1%STS inheat-defibrinatedpooledNP (PNP, 30min, 56 C)
neat and after centrifugation (10 min at 16,100 g); and
4 Purified fibrinogen (Fibrinogen Fraction 1, type I Sigma
Cat F3879) added to the VIDAS kit diluent to
a concentration of 2.3 g l1 and then spiked with STS.
Presentation of Sampling Fluctuations
Sampling fluctuations are reflected by the standard errors
(standard deviation divided by the square root of the
number of sample) for Figures 1, 5 and 6 and within the
10-15 % range for the remaining Figures.
Results
Clot kinetics
Low concentrations (0.075e0.1%)
Strong clots (amplitude >20 mm) were formed in TEG and
all ROTEM assays (Fig. 1(b)). The reaction (r)/clotting time(CT) and coagulation time (k)/clot formation time (CFT)
were reduced in TEG and NATEM (Fig. 1(c)) while the clot
formation rate (CFR) was increased (results not shown).
TEG Coagulation Index showed a hypercoagulable state
(CI > þ3.0).
Midrange concentrations (0.15% STS, 0.15e0.3% POL)
Weak clots (amplitude <20 mm) formed in all assays except
in FIBTEM where the amplitude remained within the normal
range of 9e25 mm (Fig. 1(b) and (c)). This indicated an
inhibition of platelet contribution to clot firmness. In tissue
factor (TF)-based assays (EXTEM, APTEM and FIBTEM),
weak clots formed at 0.3% STS but clot formation was
inhibited at higher concentrations.
High concentrations (‡0.3% STS, ‡0.6% POL)
Both agents inhibited clot formation and indefinitely pro-
longed r/CT and k/CFT (Fig. 1(b) and (c)). CFR was reduced
to zero. No value for TEG CI could be obtained
(CI < 3.0), indicating a hypocoagulable state.
Other findings
Addition of aprotinin (APTEM) did not influence the
maximum amplitude as compared with EXTEM and, hence,
no fibrinolysis was detected. Direct prothrombin activation
(ECATEM) yielded results similar to other non-TF-based
assays.
Figure 4 Effect of increasing concentrations of sclerosants
on fibrinogen levels. (n Z 2, - STS and  POL).
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t-PA at 25 ng ml1 within a 50% diluted plasma clot induced
clot lysis within 6 h. STS at 0.1% shortened CLT to 4 h and
at 0.15% to <2 h (Fig. 2). POL had less effect.
Interaction with exogenous t-PA
t-PA was inactivated by STS at 0.4% in plasma while POL
had less effect (Fig. 3). STS interfered more with t-PA
activity in protein-poor buffer, whereas, in plasma (which
is protein rich), 10 higher levels of STS were required
due to protein binding.
Fibrinogen
STS at 0.3% reduced fibrinogen levels in plasma by 20%, and
at 0.6% destroyed this protein completely (Fig. 4). POL
had minimal effect.
FXIII
STS at 0.075% reduced FXIII to less than 50%, and at 0.15%
completely destroyed this protein in WB (Fig. 5). POL had
minimal effect. Similar results were obtained in PRP and PPP
samples (results not shown). Control experiments showed no
interaction with the assay system (results not shown).Figure 3 Effect of STS (3a) and POL (3b) on t-PA induced
fibrinolysis (n Z 2, STS: A t Z 0, - t Z 1hr, : t Z 2hr, 
t Z 3hr, )t Z 4hr) (POL: A t Z 0; - t Z 1hr, : t Z 2hr, 
t Z 3hr, )t Z 4hr).Fibrinolytic activity
STS at >0.4% solubilised non-cross-linked fibrin, but at 3%
demonstrated a significant lytic effect (Fig. 6(a)). STS had
a similar effect to t-PA but was 100,000 times weaker on
a direct concentration basis. POL had little effect on non-
cross-linked fibrin. Both agents showed no significant effect
on cross-linked fibrin agarose gels (Fig. 6(b)) or cross-linked
fibrin powder (results not shown).
D-dimer
In VIDAS assay, STS at 0.6% significantly elevated the D-
dimer levels to 2.5 mg l1 (normal range 0e0.5 mg l1)
while POL had no effect (results not shown). This elevation
was not detected by AxSYM or STALiatest.
Removal of a previously reported STS-induced precipi-
tate2 did not influence the D-dimer elevation. STS dilutions
in saline, in VIDAS kit diluent (w0.6 mg l1) and in heat-
defibrinated PNP showed no measurable D-dimer levels.
However, STS spiking of the VIDAS kit diluent to which
purified fibrinogen was added caused elevations of D-
dimer (up to 7.4 mg l1 with 1% STS). Therefore, fibrinogen
was required for the STS-induced elevation of D-dimer, as
measured by the VIDAS assay.Figure 5 Effect of increasing concentrations (0%, 0.075%,
0.15%, 0.3%, 0.6%, 1.2%) of sclerosants on factor XIII levels in
whole blood. (n Z 4, - STS and  POL).
Figure 6 Comparison of fibrinolytic activity of detergent
sclerosants with that of t-PA on cross-linked (6a) and non-cross-
linked (6b) fibrin. Only results obtained with 3% sclerosants are
shown as they are typical. (n Z 3, -STS  105,  POL  105
and :t-PA).
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Detergent sclerosants are used clinically to occlude vessels.
The sequence of events leading to vessel occlusion has
been unknown and whether clot formation plays a part in
this process has been debated. In this study, both agents
demonstrated a trimodal effect on clot formation and
firmness (Fig. 7). At low concentrations (0.075e0.1%), clot
formation was enhanced by both agents as manifested by
the formation of strong clots (>20 mm amplitude) in all
assays. In addition, strong clots were initiated by both
agents in the non-activated NATEM assay, in the absence
of any activators, and where the only reagent added was
CaCl2 for re-calcification purposes. The clotting and
clot formation times were shortened in NATEM and TEG
and the Coagulation Index showed a hypercoagulable state.
This procoagulant activity is consistent with the release
of platelet-derived microparticles (PMPs) and shortening
of phospholipid-dependent Xa and surface-activated
clotting times (XACT and SACT) previously reported by this
group.2,10 At midrange concentrations (0.15% STS,
0.15e0.3% POL), both agents induced weak clots (<20 mm
amplitude). There was a reduction of amplitude in EXTEM
while the amplitude in FIBTEM remained within normallimits, indicating a lack of contribution from platelets to
clot formation and firmness. At higher concentrations
(0.6e1.2%), no clots were formed, indicating clotting factor
and, in particular, fibrinogen deficiency. This confirms our
previous reports that both agents at high concentrations
bind phospholipids, destroy a number of clotting factors
and inhibit clotting interactions.2,3
We investigated whether clots formed in presence of
sclerosants were more prone to lysis. Although both agents
increased the clot lysis rates at midrange concentrations,
there was no synergistic (or inhibitory) effect between
the detergents and t-PA. At higher concentrations, STS (but
not POL) had an inhibitory effect on t-PA-induced fibrino-
lysis most likely due to denaturation of the t-PA protein
structure. Plasminogen, the main t-PA substrate, is also
destroyed by STS at such high concentrations.4 Hence, the
faster clot lysis rates were not due to a synergistic inter-
action with t-PA but due to formation of weak clots
susceptible to lysis as confirmed by thromboelastometry.
Clot strength is affected by fibrinogen,11 FXIII12 and
platelets.13 We found all three to be affected by midrange
concentrations of STS while POL had no effect on fibrinogen
or FXIII. High fibrinogen concentrations are required for
increased clot rigidity14 and density.11 In this study, fibrin-
ogen levels were reduced at midrange concentrations of
STS and, at 0.6%, this protein was completely destroyed.
Consistently, the FIBTEM signal was lost at 0.6% STS. This is
most likely due to denaturation and unfolding of the
fibrinogen protein structure.15 Furthermore, both cationic
and anionic detergents precipitate fibrinogen by forming
fibrinogenedetergent complexes.2,16
In this study, FXIII was destroyed by STS at 0.15%. FXIIIa
covalently cross-links fibrin monomers to form cross-linked
fibrin. This enhances clot stability and increases resistance
to fibrinolysis and deformation.5 Apart from its cross-linking
function, FXIIIa covalently binds inhibitors of fibrinolysis,
such as antiplasmin, to the fibrin clot. This is possibly the
main mechanism by which FXIIIa increases the resistance of
the clot to lysis.17 Destruction of FXIII prevents cross-link-
ing, reduces clot firmness and leads to formation of weak
and unstable clots susceptible to lysis.12
Platelet contribution to clot firmness plays an important
role in clot amplitude in thromboelastometry.18 Comparing
the clot firmness in FIBTEM (where platelets are blocked)
with EXTEM (includes platelet contribution), midrange
concentrations of both sclerosants showed a lack of
contribution from platelets to clot firmness. This is consis-
tent with our earlier reports that both agents at similar
concentrations (0.15%) induce platelet lysis.2,10
We investigated the fibrinolytic activity of sclerosants.
Both agents had no destructive effect on cross-linked
fibrin and, consistently, no fibrinolysis was detected in
APTEM. However, STS destroyed non-cross-linked fibrin and
produced a similar dose response curve to t-PA although
approximately 100,000 times weaker. This is possibly due
to depolymerisation of the non-cross-linked fibrin polymer
by STS. Similarly, plasmin has less effect on cross-linked
fibrin19 and the presence of FXIIIa slows down the process
of clot lysis induced by t-PA.20 A similar anionic detergent,
sodium dodecyl sulphate (SDS), also exhibits some fibrino-
lytic activity.21 The process of cross-linking happens very
quickly and non-cross-linked fibrin is normally not present
Figure 7 Cartoons demonstrating the observed effects of STS (a) and POL (b) on clot formation. The effect demonstrated is at
the point of entry of sclerosants into the target vessel where the sclerosant concentration is at its highest and downstream where
the concentration drops. High concentration (>0.3%) STS destroys fibrinogen, factor XIII (FXIII), thrombin (T)2 and platelets (PLT)
and a number of other clotting factors2 and in this study inhibited clot formation. High concentration (>0.6%) POL destroys
platelets and a number of clotting factors2 and in this study also inhibited clot formation. At midrange concentrations (0.15% STS,
0.15e0.3% POL), both agents inhibited the contribution of platelets to clot firmness and generated weak clots. 0.15% STS destroyed
FXIII and reduced fibrinogen. Both agents at low concentrations (0.075% and 0.1%) initiated and enhanced strong clot formation.
Cn., concentration; FXIIIa, activated FXIII; XL, cross-linked; NXL, non-cross-linked.
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clot would not lead to detectable lysis. POL, a non-ionic
detergent, demonstrated no fibrinolytic activity. Non-ionic
and zwitterionic detergents are reported to increase the
apparent activity of t-PA, although they have little net
thrombolytic23 or fibrinolytic activity.21
In this study, high-concentration STS caused an arte-
factual elevation of D-dimer levels when measured in the
VIDAS ELISA assay. This only occurred when fibrinogen
was present in the sample. One possible mechanism is that
STS caused a conformational change in fibrinogen, exposingan epitope recognised by monoclonal antibodies used in
the VIDAS assay, but not in the other two commercial
assays tested. Fibrinogen can form flexible polymer chains
similar to polymeric fibrin by binding end-to-end in D-dimer
configuration where the neighbouring D domains form ‘DD’
regions.24 D-dimer specific antibodies have been previously
reported to react with such soluble fibrinogen aggregates.25
Based on our present findings, high-concentration
sclerosants inhibit clot formation and hence, their modus
operandi can potentially by-pass thrombosis to achieve
fibrosis. However, given that these agents act rapidly,
276 K. Parsi et al.prolonged high intravascular concentrations are unlikely. In
addition, although relatively high concentrations can be
achieved at the point of entry, much lower final concentra-
tions are generated when these agents are mixed with large
volumes of blood, diluted and neutralised.10
Foam sclerosants are more effective than liquid agents,
possibly due to displacement of blood and a reduced expo-
sure to serum albumin and other plasma components. Clin-
ical recurrence, despite the use of high concentrations of
sclerosants, is most likely secondary to inadequate vascular
injury, formation of intra-vascular thrombus and subsequent
recanalisation.26 Treatment modifications aiming at mini-
mising the intra-vascular blood content may achieve higher
final concentrations and a lower recanalisation rate.
Clinically, sclerotherapy has been associated with
thrombo-embolic complications, including paradoxical clot
embolism and stroke, following the use of low- to midrange
concentrations of sclerosants.27 Clot formation normally
occurs due to interaction of running blood from the
adjoining patent vessels reaching the site of vascular injury.
The subsequent activation of platelets and the coagulation
system would result in clot formation. Formation of such
clots is initiated by vascular injury. Based on our present
findings, clots can also be initiated directly by low- to
midrange concentrations of both sclerosants upon contact
with blood and in the absence of vascular damage. The
formation of such clots and their viscoelastic properties
would depend on the final intra-vascular concentrations
achieved. A weak clot deficient in FXIII, as that formed
by midrange concentrations of sclerosants, would have the
potential for detachment from the vessel wall and embo-
lisation, as well as lysis and clinical recanalisation.
This study was not without limitations. We did not use
the euglobulin clot lysis time method as it remains
a complex and time-consuming procedure. The in vivo
effects of sclerosants on clot formation and lysis, including
the effects of foam sclerosants, are currently being inves-
tigated by this group in other studies. We report that low-
concentration sclerosants initiate a platelet-dependent
clot formation process. Platelets play a small role in venous
thrombosis and subsequently there have been no system-
atic studies on the effects of sclerosants on platelets and
the influence of platelet inhibitors on sclerotherapy treat-
ment outcomes. Given our current findings, these topics
may require further evaluation.
Summary
Sclerosants demonstrated a trimodal effect on clot forma-
tion whereby, at low concentrations (0.075e0.1%), they
enhanced strong clot formation, at midrange concentra-
tions (0.15% STS, 0.15e0.3% POL) induced weak clots
susceptible to lysis and, at higher concentrations, pre-
vented clot formation. Neither agent had a lytic effect on
cross-linked fibrin but high-concentration STS destroyed
non-cross-linked fibrin. STS caused an artefactual elevation
of D-dimer in the VIDAS assay.
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